UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Overview of hypertrophic cardiomyopathy management including treatment of special problems

Author
Martin S Maron, MD
Section Editor
William J McKenna, MD
Deputy Editor
Brian C Downey, MD, FACC

INTRODUCTION

Hypertrophic cardiomyopathy (HCM) is a genetically determined heart muscle disease most often (60 to 70 percent) caused by mutations in one of several sarcomere genes which encode components of the contractile apparatus. (See "Hypertrophic cardiomyopathy: Gene mutations and clinical genetic testing".)

HCM is characterized by left ventricular hypertrophy of various morphologies, with a wide array clinical manifestations and hemodynamic abnormalities. Depending in part upon the site and extent of cardiac hypertrophy, HCM patients can develop one or more of the following abnormalities:

These structural and functional abnormalities can produce a variety of symptoms, including:

  • Fatigue
  • Dyspnea
  • Chest pain
  • Palpitations
  • Presyncope or syncope

                

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Dec 06 00:00:00 GMT 2012.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Oakley GD, McGarry K, Limb DG, Oakley CM. Management of pregnancy in patients with hypertrophic cardiomyopathy. Br Med J 1979; 1:1749.
  2. Autore C, Conte MR, Piccininno M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40:1864.
  3. Maron BJ, Spirito P, Wesley Y, Arce J. Development and progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy. N Engl J Med 1986; 315:610.
  4. Ryan MP, Cleland JG, French JA, et al. The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. Am J Cardiol 1995; 76:689.
  5. Nugent AW, Daubeney PE, Chondros P, et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 2005; 112:1332.
  6. Maron BJ, Tajik AJ, Ruttenberg HD, et al. Hypertrophic cardiomyopathy in infants: clinical features and natural history. Circulation 1982; 65:7.
  7. Colan SD, Lipshultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007; 115:773.
  8. Yang Z, McMahon CJ, Smith LR, et al. Danon disease as an underrecognized cause of hypertrophic cardiomyopathy in children. Circulation 2005; 112:1612.
  9. Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2008; 358:1899.
  10. Shirani J, Pick R, Roberts WC, Maron BJ. Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. J Am Coll Cardiol 2000; 35:36.
  11. Yetman AT, Hamilton RM, Benson LN, McCrindle BW. Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998; 32:1943.
  12. Yetman AT, McCrindle BW, MacDonald C, et al. Myocardial bridging in children with hypertrophic cardiomyopathy--a risk factor for sudden death. N Engl J Med 1998; 339:1201.
  13. Mohiddin SA, Begley D, Shih J, Fananapazir L. Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. J Am Coll Cardiol 2000; 36:2270.
  14. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993; 22:796.
  15. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol 1999; 34:1813.
  16. Rishi F, Hulse JE, Auld DO, et al. Effects of dual-chamber pacing for pediatric patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 1997; 29:734.
  17. Stone CD, McIntosh CL, Hennein HA, et al. Operative treatment of pediatric obstructive hypertrophic cardiomyopathy: a 26-year experience. Ann Thorac Surg 1993; 56:1308.
  18. Watkins H, McKenna WJ. The prognostic impact of septal myectomy in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46:477.
  19. Yetman AT, McCrindle BW. Management of pediatric hypertrophic cardiomyopathy. Curr Opin Cardiol 2005; 20:80.
  20. Hardarson T, De la Calzada CS, Curiel R, Goodwin JF. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. Lancet 1973; 2:1462.
  21. Shah PM, Adelman AG, Wigle ED, et al. The natural (and unnatural) history of hypertrophic obstructive cardiomyopathy. Circ Res 1974; 35:suppl II:179.
  22. Pasquale G Di, Andreoli A, Lusa AM, et al. Cerebral embolic risk in hypertrophic cardiomyopathy. In: Advances in Cardiomyopathies, Baroldi G, Camerini F, Goodwin JF (Eds), Springer-Verlag, 1990. p.90.
  23. Spirito P, Rapezzi C, Bellone P, et al. Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis. Circulation 1999; 99:2132.
  24. Thompson RC, Liberthson RR, Lowenstein E. Perioperative anesthetic risk of noncardiac surgery in hypertrophic obstructive cardiomyopathy. JAMA 1985; 254:2419.
  25. Haering JM, Comunale ME, Parker RA, et al. Cardiac risk of noncardiac surgery in patients with asymmetric septal hypertrophy. Anesthesiology 1996; 85:254.
  26. Poliac LC, Barron ME, Maron BJ. Hypertrophic cardiomyopathy. Anesthesiology 2006; 104:183.
  27. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2009; 120:e169.